Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 472 Jan 1 – Oct 24, 2026
- Disclosed funding
- $19.6B 400 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| F FlinnCompany profile Develops AI-based software to automate regulatory and quality processes in medtech and pharma Develops AI-based software to automate regulatory and quality processes in medtech and pharma | $20M | Series A | Biotech, Healthtech | Austria | Investors | |
| KB Develops therapies for neurodegenerative diseases. | $175M | Series A | Biotech | United States | Investors | |
| SP Develops next-generation peptide radioligand therapies for cancer | $18M | Series A | Biotech | United States | Investors | |
| P Pharmacelera uses quantum-mechanics methods and AI in drug discovery. | €6M | Growth | Biotech | Spain | Investors | |
| SB Sift BiosciencesCompany profile Develops next-generation peptide immunotherapy platform using AI metagenomics and high-throughput profiling to engage memory T cells for cancer and autoimmune diseases Develops next-generation peptide immunotherapy platform using AI metagenomics and high-throughput profiling to engage memory T cells for cancer and autoimmune diseases | $3.7M | Pre-SeedPre-seed | Biotech | United States | Investors | |
| BT Develops precision immune therapies for glioblastoma | €2.5M | StrategicUndisclosed | Biotech | Sweden | Investors | |
| SL Seek LabsCompany profile Develops a programmable disease response platform to detect protect and counter disease threats Develops a programmable disease response platform to detect protect and counter disease threats | $2M | GrantUndisclosed | Biotech | United States | Investors | |
| G GelMEDIXCompany profile Develops regenerative therapies to restore vision by regenerating damaged retinal cells Develops regenerative therapies to restore vision by regenerating damaged retinal cells | $13M | Seed | Biotech | United States | Investors | |
| B Provides AI-powered platform for bioprocess development and optimization | Undisclosed | StrategicUndisclosed | Biotech | United States | Investors | |
| OM OncoRes MedicalCompany profile Develops a hand-held real-time intraoperative imaging device to improve the detection of residual cancer during surgery Develops a hand-held real-time intraoperative imaging device to improve the detection of residual cancer during surgery | $27M | Growth | Biotech, Healthtech | Australia | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.